Management of Chemotherapy Tissue Extravasation

  • Kerry VanSloten Harwood
  • Janice Johnstone Strauman


Although the occurrence of inadvertent tissue extravasation during the administration of chemotherapy is relatively infrequent, this problem is important because of the severe tissue necrosis that may develop at the extravasation site. Several issues are of interest in consideration of this clinical problem: (1) Controversy exists as to which administration methods should be used to prevent an extravasation. (2) The diagnosis of an extravasation must be differentiated from that of other local toxicities of chemotherapy that may present with similar symptoms. (3) Surgical interventions have been refined to increase the success rate of the graft or flap applied after surgical debridement. (4) Numerous potential antidotes have been tested in an attempt to prevent subsequent necrosis after an extravasation occurs. Each of these areas is considered after a review of the problem.


Vinca Alkaloid Chemotherapy Administration Local Toxicity Extravasation Site Local Tissue Damage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Leyden M, Sullivan J: Full thickness skin necrosis due to inadvertent interstitial infusion of cisplatin. Cancer Treatment Rep 67: 199, 1983.Google Scholar
  2. 2.
    Teta JB, O’Connor L: Local tissue damage from 5-fluorouracil extravasation. Oncol Nurs Forum 11: 77, 1984.PubMedGoogle Scholar
  3. 3.
    Karp G, Antman K, Canellos G: VP16–213: A phase II trial using a weekly schedule. Cancer Clin Trials 4: 465–467, 1981.PubMedGoogle Scholar
  4. 4.
    Duvall E, Baumann B: An unusual accident during the administration of chemotherapy. Cancer Nurs, Aug, pp 305–306, 1980.Google Scholar
  5. 5.
    Dorr RT: Extravasation of vesicant antineoplastics: Clinical and experimental findings. Ariz Med 38: 271–274, 1981.PubMedGoogle Scholar
  6. 6.
    Dorr RT, Alberts DS: Vinca alkaloid skin toxicity: Antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74: 113–120, 1985.PubMedGoogle Scholar
  7. 7.
    Dorr RT, Jones SE: Inapparent infiltrations associated with vindesine administration. Med Pediatr Oncol 6: 285–288, 1979.PubMedCrossRefGoogle Scholar
  8. 8.
    Rudolph R, Stein RS, Patillo R: Skin ulcers due to adriamycin. Cancer 38: 1087–1094, 1976.PubMedCrossRefGoogle Scholar
  9. 9.
    Reilly JJ, Neifeld JP, Rosenberg SA: Clinical course and management of accidental adriamycin extravasation. Cancer 40: 2053–2056, 1977.PubMedCrossRefGoogle Scholar
  10. 10.
    Bowers DG Jr, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 61: 86–92, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treatment Rev 7: 17–27, 1980.CrossRefGoogle Scholar
  12. 12.
    Johnston-Early A, Cohen M: Mitomycin C-induced skin ulceration remote from infusion site. Cancer Treatment Rep 65: 529, 1981.Google Scholar
  13. 13.
    Argenta LC, Manders EK: Mitomycin C extravasation injuries. Cancer 51: 1080–1082, 1983.PubMedCrossRefGoogle Scholar
  14. 14.
    Wood HA, Ellerhorst-Ryan JM: Delayed adverse skin reactions associated with mitomycin C administration. Oncol Nurs Forum 11: 14–18, 1984.PubMedGoogle Scholar
  15. 15.
    Bartowski-Dodds L, Reville B: Extensive tissue ulceration due to apparent sensitivity reactions with mitomycin. Cancer Treatment Rep 69: 925–926, 1985.Google Scholar
  16. 16.
    Khanna AK, Khanna A, Asthana AK, Misra, MK: Mitomycin C extravasation ulcers. J. Surg Oncol 28: 108–110, 1985.PubMedCrossRefGoogle Scholar
  17. 17.
    Vogelzang NJ: “Adriamycin flare”: A skin reaction resembling extravasation. Cancer Treatment Rep 63:2067–2069, 1979.Google Scholar
  18. 18.
    Etcubanas E, Wilbur JR: Uncommon side effects of adriamycin. Cancer Chemother Rep 58: 757–758, 1974.PubMedGoogle Scholar
  19. 19.
    Perry DJ, Weiss RB, Hoth DF: Hypersensitivity reactions to amsacrine. Cancer Treatment Rep 69: 199–201, 1985.Google Scholar
  20. 20.
    Glass EC: Aclacinomycin A flare. Cancer Treatment Rep 66: 1683, 1982.Google Scholar
  21. 21.
    Loth TS: Minimal surgical debridement for the treatment of chemotherapeutic agent skin extravasation (abstract). Proc Am Soc Clin Oncol 4: 275, 1985.Google Scholar
  22. 22.
    Sonneveld P, Wassenaar HA, Nooter K: Long persistence of doxorubicin in human skin after extravasation. Cancer Treatment Rep 68: 895–896, 1984.Google Scholar
  23. 23.
    Linder RM, Upton J, Osteen R: Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg 8: 32–38, 1983.Google Scholar
  24. 24.
    Cohen FJ, Manganaro J, Bezozo RC: Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis. J Hand Surg 8: 43–45, 1983.Google Scholar
  25. 25.
    Larson DL: Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796–1799, 1982.PubMedCrossRefGoogle Scholar
  26. 26.
    Barlock AL, Howser DM, Hubbard SM: Nursing management of adriamycin extravasation. Am J Nurs 79: 94–96, 1979.PubMedGoogle Scholar
  27. 27.
    Cohen MH: Amelioration of adriamycin skin necrosis: An experimental study. Cancer Treatment Rep 63: 1003–1004, 1979.Google Scholar
  28. 28.
    Siegel DM, Girl SN, Scheinholtz RM, et al: Characteristics and effect of antiinflammatory drugs on adriamycin-induced inflammation in the mouse paw. Inflammation 4: 233–247, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Barr RD, Sertie J: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: A study of active intervention. Br J Cancer 44: 267–268, 1981.CrossRefGoogle Scholar
  30. 30.
    VanSloten KL, Gee MV, Bachur N, et al: Treatment of doxorubicin extravasation in a rat model (abstract ). Proc Oncol Nurs Soc Congr, 1982.Google Scholar
  31. 31.
    Dorr RT, Alberts DS, Chen HSG: The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol 5: 17–20, 1980.PubMedCrossRefGoogle Scholar
  32. 32.
    Dorr RT, Alberts DS, Stone A: Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Tretment Rep 69: 431–437, 1985.Google Scholar
  33. 33.
    Harwood KV, Bachur N: Evaluation of dimethyl sulfoxide and local cooling as antidotes for doxorubicin extravasation in a pig model. Oncology Nursing Forum 14 (1): 39–44, 1987.PubMedGoogle Scholar
  34. 34.
    Bartowski-Dodds L, Daniels JR: Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats. Cancer Chemother Pharmacol 4: 179–181, 1980.Google Scholar
  35. 35.
    Zweig JL, Kabakow B: An apparently effective countermeasure for doxorubicin extravasation. J Am Med Assoc 239: 2116, 1979.CrossRefGoogle Scholar
  36. 36.
    Okano T, Ohnuma T, Efremidis A, Holland JF: Doxorubicin-induced skin ulcer in the piglet. Cancer Treatment Rep 67: 1075–1078, 1983.Google Scholar
  37. 37.
    Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.PubMedCrossRefGoogle Scholar
  38. 38.
    Desai MH, Teres D: Prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO). Cancer Treatment Rep 66: 1371–1374, 1982.Google Scholar
  39. 39.
    Svingen BA, Powis G, Appel PL, et al: Protection against adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and alpha tocopherol. Cancer Res 41: 3395–3399, 1981.PubMedGoogle Scholar
  40. 40.
    Dorr RT, Alberts DS: Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treatment Rep 67: 499–501, 1983.Google Scholar
  41. 41.
    Dorr RT, Alberts DS: Pharmacologic antidotes in experimental doxorubicin skin toxicity: A suggested role for beta-adrenergic compounds. Cancer Treatment Rep 65: 1001–1005, 1981.Google Scholar
  42. 42.
    Laurie SWS, Wilson KL, Kernahan DA: Intravenous extravasation injuries: The effectiveness of hyaluronidase in their treatment. Ann Plast Surg 13: 191–194, 1984.PubMedCrossRefGoogle Scholar
  43. 43.
    Daugherty JP, Khurana A: Amelioration of doxorubicin-induced skin necrosis in mice by butylated hydroxytoluene. Cancer Chemother Pharmacol 14: 242–246, 1985.CrossRefGoogle Scholar
  44. 44.
    Dorr RT: Chemotherapy extravasation (editorial). Meniscus Health Care Communications, May/June, 1984.Google Scholar
  45. 45.
    Owens G, Hatiboglu I: Clinical evaluation of sodium thiosulphate as a systemic neutralizer of nitrogen mustard. Ann Surg 154: 895–897, 1961.PubMedGoogle Scholar
  46. 46.
    Owen O, Dellatore D: Accidental intramuscular injection of mechlorethamine. Cancer 45: 2225–2226, 1980.PubMedCrossRefGoogle Scholar
  47. 47.
    Howell S, Pfeifle C, Wung W, et al: Intraperitoneal cis-diammine-dichloroplatinum with systemic thiosulphate protection. Cancer Res 43: 1426–1431, 1983.PubMedGoogle Scholar
  48. 48.
    Dorr RT, Alberts DJ: Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. Invest New Drugs 1: 151–159, 1983.Google Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Kerry VanSloten Harwood
    • 1
  • Janice Johnstone Strauman
    • 2
    • 3
  1. 1.Johns Hopkins Oncology CenterBaltimoreUSA
  2. 2.Department of OncologyAlbert Einstein Cancer Center/Montefiore Medical CenterBronxUSA
  3. 3.Columbia University School of NursingNew YorkUSA

Personalised recommendations